Pfizer ( NYSE: PFE ) shares traded in the red on Monday, making it the seventh consecutive day of losses. The stock closed down 0.35% at $28.
45. PFE stock fell about 20.5% in the last 12 months.
YTD, the stock is trading down 1.49%, compared to the broader S&P 500 market which is up 12.04%.
Looking at Seeking Alpha's Quant Ratings, this company has a Hold rating with a score of 3.47 out of 5. When it comes to Wall Street analysis, 15 out of 25 analysts recommend a Hold, 6 recommend a Strong Buy and 4 recommend a Buy.
According to ALLKA Research, “I believe the company's stock will continue to rally due to the progress made in the development of its pipeline of experimental drugs, including encouraging pharmacokinetic data for the once-daily formulation of danuglipron being developed for the treatment of obesity and type 2 diabetes, as well as the potential approval of Ngenla, a long-acting recombinant human growth hormone, by the EMA.” Seeking Alpha analysts have a Buy rating on the company. More on Pfizer Pfizer: Tracking Well Above The Industry Pfizer Stock: It May Be Just The Beginning Of A Solid Rally Merck / Pfizer Earnings Summaries: Staying With Merck For Now, Pfizer's Cost-Cutting Will Help Margins Pfizer’s RSV vaccine shows strong response in immunocompromised adults Pfizer Tagrisso patent case against AstraZeneca upheld by judge.